WO2001085947A3 - Compounds and methods for the diagnosis and treatment of babesia microti infection - Google Patents

Compounds and methods for the diagnosis and treatment of babesia microti infection Download PDF

Info

Publication number
WO2001085947A3
WO2001085947A3 PCT/US2001/015192 US0115192W WO0185947A3 WO 2001085947 A3 WO2001085947 A3 WO 2001085947A3 US 0115192 W US0115192 W US 0115192W WO 0185947 A3 WO0185947 A3 WO 0185947A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptides
compounds
diagnosis
treatment
methods
Prior art date
Application number
PCT/US2001/015192
Other languages
French (fr)
Other versions
WO2001085947A2 (en
Inventor
Steven G Reed
Michael J Lodes
Raymond L Houghton
Paul R Sleath
Patricia D Mcneill
Mary J Homer
Heather Secrist
Original Assignee
Corixa Corp
Steven G Reed
Michael J Lodes
Raymond L Houghton
Paul R Sleath
Patricia D Mcneill
Mary J Homer
Heather Secrist
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/569,098 external-priority patent/US6569433B1/en
Priority claimed from US09/737,178 external-priority patent/US20010029295A1/en
Application filed by Corixa Corp, Steven G Reed, Michael J Lodes, Raymond L Houghton, Paul R Sleath, Patricia D Mcneill, Mary J Homer, Heather Secrist filed Critical Corixa Corp
Priority to AU2001261416A priority Critical patent/AU2001261416A1/en
Priority to EP01935311A priority patent/EP1285068A2/en
Publication of WO2001085947A2 publication Critical patent/WO2001085947A2/en
Publication of WO2001085947A3 publication Critical patent/WO2001085947A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56905—Protozoa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Compounds and methods for the diagnosis and treatment of B. microti infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of a B. microti antigen and DNA sequences encoding such polypeptides. Antigenic epitopes of such antigens are also provided, together with pharmaceutical compositions and immunogenic compositions comprising such polypeptides, DNA sequences or antigenic epitopes. Diagnostic kits containing such polypeptides, DNA sequences or antigenic epitopes and a suitable detection reagent may be used for the detection of B. microti infection in patients and biological samples. Antibodies directed against such polypeptides and antigenic epitopes are also provided.
PCT/US2001/015192 2000-05-10 2001-05-09 Compounds and methods for the diagnosis and treatment of babesia microti infection WO2001085947A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2001261416A AU2001261416A1 (en) 2000-05-10 2001-05-09 Compounds and methods for the diagnosis and treatment of babesia microti infection
EP01935311A EP1285068A2 (en) 2000-05-10 2001-05-09 Compounds and methods for the diagnosis and treatment of babesia microti infection

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US09/569,098 2000-05-10
US09/569,098 US6569433B1 (en) 1996-10-01 2000-05-10 Compounds and methods for the diagnosis and treatment of B. microti infection
US60572400A 2000-06-27 2000-06-27
US09/605,724 2000-06-27
US65668800A 2000-09-07 2000-09-07
US09/656,688 2000-09-07
US68543600A 2000-10-10 2000-10-10
US09/685,436 2000-10-10
US09/737,178 US20010029295A1 (en) 1996-10-01 2000-12-13 Compounds and methods for the diagnosis and treatment of B. microti infection
US09/737,178 2000-12-13
US79476401A 2001-02-26 2001-02-26
US09/794,764 2001-02-26

Publications (2)

Publication Number Publication Date
WO2001085947A2 WO2001085947A2 (en) 2001-11-15
WO2001085947A3 true WO2001085947A3 (en) 2002-12-05

Family

ID=27560142

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/015192 WO2001085947A2 (en) 2000-05-10 2001-05-09 Compounds and methods for the diagnosis and treatment of babesia microti infection

Country Status (3)

Country Link
EP (1) EP1285068A2 (en)
AU (1) AU2001261416A1 (en)
WO (1) WO2001085947A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8283124B2 (en) * 2007-10-25 2012-10-09 Abbott Laboratories Compositions for detecting antibodies to Babesia microti and methods of uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0834567A2 (en) * 1996-10-01 1998-04-08 Corixa Corporation Compounds and methods for the diagnosis and treatment of Babesia microti infection
WO1999029869A1 (en) * 1997-12-11 1999-06-17 Corixa Corporation Compounds and methods for the diagnosis and treatment of b. microti infection
WO2000060090A1 (en) * 1999-04-05 2000-10-12 Corixa Corporation Compounds and methods for the diagnosis and treatment of b. microti infection

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0834567A2 (en) * 1996-10-01 1998-04-08 Corixa Corporation Compounds and methods for the diagnosis and treatment of Babesia microti infection
WO1999029869A1 (en) * 1997-12-11 1999-06-17 Corixa Corporation Compounds and methods for the diagnosis and treatment of b. microti infection
WO2000060090A1 (en) * 1999-04-05 2000-10-12 Corixa Corporation Compounds and methods for the diagnosis and treatment of b. microti infection

Also Published As

Publication number Publication date
WO2001085947A2 (en) 2001-11-15
EP1285068A2 (en) 2003-02-26
AU2001261416A1 (en) 2001-11-20

Similar Documents

Publication Publication Date Title
WO2002008267A3 (en) Compounds and methods for treatment and diagnosis of chlamydial infection
WO2001081379A3 (en) Compounds and methods for treatment and diagnosis of chlamydial infection
WO2001040474A3 (en) Compounds and methods for treatment and diagnosis of chlamydial infection
WO2000034483A3 (en) Compounds and methods for treatment and diagnosis of chlamydial infection
WO1998042740A3 (en) Compounds and methods for the diagnosis and treatment of ehrlichia infection
WO2001062893A3 (en) Compounds and methods for diagnosis and immunotherapy of tuberculosis
WO2003041560A3 (en) Compounds and methods for treatment and diagnosis of chlamydial infection
WO2003086308A3 (en) Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
WO1998053076A3 (en) Compounds for diagnosis of tuberculosis and methods for their use
WO2000000615A3 (en) Compounds and methods for the diagnosis and treatment of ehrlichia infection
WO2002002131A3 (en) Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
EP0834567A3 (en) Compounds and methods for the diagnosis and treatment of Babesia microti infection
WO2001085949A3 (en) Compounds and methods for the diagnosis and treatment of ehrlichia infection
WO2002053016A3 (en) Compounds and methods for the diagnosis and treatment of babesia infection
WO2001085947A3 (en) Compounds and methods for the diagnosis and treatment of babesia microti infection
WO2003020108A3 (en) Compositions and methods for the diagnosis and treatment of herpes simplex virus infection

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001935311

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001935311

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001935311

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP